Free Trial
NASDAQ:MLYS

Mineralys Therapeutics Q1 2025 Earnings Report

Mineralys Therapeutics logo
$14.70 +0.24 (+1.63%)
Closing price 05/7/2025 03:59 PM Eastern
Extended Trading
$14.57 -0.13 (-0.85%)
As of 08:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.02
Beat/Miss
N/A
One Year Ago EPS
N/A

Mineralys Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mineralys Therapeutics Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Mineralys Therapeutics Earnings Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More Mineralys Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email.

About Mineralys Therapeutics

Mineralys Therapeutics (NASDAQ:MLYS), a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

View Mineralys Therapeutics Profile

More Earnings Resources from MarketBeat